Cancer drug maker Genfleet joins Hong Kong IPO influx
The biotech can boast a long list of big-name backers and has brought a promising drug to the market with its partner Innovent, but its cash reserves are dwindling Key…
Recent Articles
RELATED ARTICLES
-
Innovent ditches low-value stake sale after investor outcry
1801.HK -
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
